Predicting drug-induced QT prolongation and torsades de pointes

Journal of Physiology

Volumn 594, Issue 9, 2016, Pages 2459-2468

  Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ARSENIC TRIOXIDE; ASTEMIZOLE; CISAPRIDE; DOFETILIDE; DROPERIDOL; DRUG; FEXOFENADINE; GREPAFLOXACIN; HALOPERIDOL; KETOCONAZOLE; MESORIDAZINE; METHADONE; NEUROLEPTIC AGENT; NILOTINIB; ONDANSETRON; PENTAMIDINE; PIMOZIDE; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNQ1; PROKINETIC AGENT; QUINIDINE; SODIUM CHANNEL NAV1.5; SOTALOL; SPARFLOXACIN; TERFENADINE; THIORIDAZINE; UNINDEXED DRUG; VANDETANIB;

ACTION POTENTIAL; AFTERDEPOLARIZATION; ARTICLE; CLINICAL PRACTICE; DEPOLARIZATION; DRUG ACTIVITY; DRUG MARKETING; DRUG METABOLISM; DRUG SCREENING; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; HEART MUSCLE CELL; HEART REPOLARIZATION; HUMAN; HYPOKALEMIA; KCNE1 GENE; KCNH2 GENE; KCNQ1 GENE; LIVER TOXICITY; LONG QT SYNDROME; MEDICAL HISTORY; MOLECULAR GENETICS; NONHUMAN; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT INTERVAL; QT PROLONGATION; REPOLARIZATION; RISK FACTOR; SCN5A GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TORSADE DES POINTES; TREATMENT DURATION; TREATMENT WITHDRAWAL; ADVERSE DRUG REACTION; ANIMAL; CARDIAC MUSCLE CELL; CHEMICALLY INDUCED; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LONG QT SYNDROME; MYOCYTES, CARDIAC; TORSADES DE POINTES;

EID: 84955566929     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/JP270526     Document Type: Article

References (62)

1. Abraham JM, Saliba WI, Vekstein C, Lawrence D, Bhargava M, Bassiouny M, Janiszewski D, Lindsay BD, Militello M, Nissen SE, Poe S, Tanaka-Esposito C, Wolski K & Wilkoff BL (2015). Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circ Arrhythm Electrophysiol 8, 772-776.
2. Altin T, Ozcan O, Turhan S, Ongun OA, Akyurek O, Karaoguz R & Guldal M (2007). Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Can J Cardiol 23, 907-908.
3. Antzelevitch C (2007). Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. Am J Physiol Heart Circ Physiol 293, H2024-H2038.
4. Antzelevitch C, Burashnikov A, Sicouri S & Belardinelli L (2011). Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm 8, 1281-1290.
5. Arking DE, Pulit SL, Crotti L, van der Harst P, Munroe PB, Koopmann TT, Sotoodehnia N, Rossin EJ, Morley M, Wang X, Johnson AD, Lundby A, Gudbjartsson DF, Noseworthy PA, Eijgelsheim M, Bradford Y, Tarasov KV, Dorr M, Muller-Nurasyid M, Lahtinen AM, Nolte IM, Smith AV, Bis JC, Isaacs A, Newhouse SJ, Evans DS, Post WS, Waggott D, Lyytikainen LP, Hicks AA, Eisele L, Ellinghaus D, Hayward C, Navarro P, Ulivi S, Tanaka T, Tester DJ, Chatel S, Gustafsson S, Kumari M, Morris RW, Naluai AT, Padmanabhan S, Kluttig A, Strohmer B, Panayiotou AG, Torres M, Knoflach M, Hubacek JA, Slowikowski K, Raychaudhuri S, Kumar RD, Harris TB, Launer LJ, Shuldiner AR, Alonso A, Bader JS, Ehret G, Huang H, Kao WH, Strait JB, Macfarlane PW, Brown M, Caulfield MJ, Samani NJ, Kronenberg F, Willeit J, Smith JG, Greiser KH, Meyer Zu Schwabedissen H, Werdan K, Carella M, Zelante L, Heckbert SR, Psaty BM, Rotter JI, Kolcic I, Polasek O, Wright AF, Griffin M, Daly MJ, Arnar DO, Holm H, Thorsteinsdottir U, Denny JC, Roden DM, Zuvich RL, Emilsson V, Plump AS, Larson MG, O'Donnell CJ, Yin X, Bobbo M, D'Adamo AP, Iorio A, Sinagra G, Carracedo A, Cummings SR, Nalls MA, Jula A, Kontula KK, Marjamaa A, Oikarinen L, Perola M, Porthan K, Erbel R, Hoffmann P, Jockel KH, Kalsch H, Nothen MM, den Hoed M, Loos RJ, Thelle DS, Gieger C, Meitinger T, Perz S, Peters A, Prucha H, Sinner MF, Waldenberger M, de Boer RA, Franke L, van der Vleuten PA, Beckmann BM, Martens E, Bardai A, Hofman N, Wilde AA, Behr ER, Dalageorgou C, Giudicessi JR, Medeiros-Domingo A, Barc J, Kyndt F, Probst V, Ghidoni A, Insolia R, Hamilton RM, Scherer SW, Brandimarto J, Margulies K, Moravec CE, Greco MF, Fuchsberger C, O'Connell JR, Lee WK, Watt GC, Campbell H, Wild SH, El Mokhtari NE, Frey N, Asselbergs FW, Mateo Leach I, Navis G, van den Berg MP, van Veldhuisen DJ, Kellis M, Krijthe BP, Franco OH, Hofman A, Kors JA, Uitterlinden AG, Witteman JC, Kedenko L, Lamina C, Oostra BA, Abecasis GR, Lakatta EG, Mulas A, Orru M, Schlessinger D, Uda M, Markus MR, Volker U, Snieder H, Spector TD, Arnlov J, Lind L, Sundstrom J, Syvanen AC, Kivimaki M, Kahonen M, Mononen N, Raitakari OT, Viikari JS, Adamkova V, Kiechl S, Brion M, Nicolaides AN, Paulweber B, Haerting J, Dominiczak AF, Nyberg F, Whincup PH, Hingorani AD, Schott JJ, Bezzina CR, Ingelsson E, Ferrucci L, Gasparini P, Wilson JF, Rudan I, Franke A, Muhleisen TW, Pramstaller PP, Lehtimaki TJ, Paterson AD, Parsa A, Liu Y, van Duijn CM, Siscovick DS, Gudnason V, Jamshidi Y, Salomaa V, Felix SB, Sanna S, Ritchie MD, Stricker BH, Stefansson K, Boyer LA, Cappola TP, Olsen JV, Lage K, Schwartz PJ, Kaab S, Chakravarti A, Ackerman MJ, Pfeufer A, de Bakker PI & Newton-Cheh C (2014). Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nat Genet 46, 826-836.
6. Ks cardiac potassium current. Nature 384, 78-80.
7. Behr ER, January C, Schulze-Bahr E, Grace AA, Kaab S, Fiszman M, Gathers S, Buckman S, Youssef A, Pirmohamed M & Roden D (2013a). The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. Eur Heart J 34, 1958-1963.
8. Behr ER, Ritchie MD, Tanaka T, Kääb S, Crawford DC, Nicoletti P, Floratos A, Sinner MF, Kannankeril PJ, Wilde AA, Bezzina CR, Schulze-Bahr E, Zumhagen S, Guicheney P, Bishopric NH, Marshall V, Shakir S, Dalageorgou C, Bevan S, Jamshidi Y, Bastiaenen R, Myerburg RJ, Schott JJ, Camm AJ, Steinbeck G, Norris K, Altman RB, Tatonetti N, Jeffery S, Kubo M, Nakamura Y, Shen Y, George AL Jr. & Roden DM (2013b). Genome wide analysis of drug-induced Torsades de Pointes: lack of common variants with large effect sizes. PloS One 8, e78511.
9. Bennett PB, Yazawa K, Makita N & George AL Jr. (1995). Molecular mechanism for an inherited cardiac arrhythmia. Nature 376, 683-685.
10. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, Gottesdiener K & Wagner JA (2008). The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 84, 475-480.
11. Crotti L, Monti MC, Insolia R, Peljto A, Goosen A, Brink PA, Greenberg DA, Schwartz PJ & George AL Jr. (2009). NOS1AP is a genetic modifier of the long-QT syndrome. Circulation 120, 1657-1663.
12. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED & Keating MT (1995). A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80, 795-803.
13. Darpo B, Garnett C, Benson CT, Keirns J, Leishman D, Malik M, Mehrotra N, Prasad K, Riley S, Rodriguez I, Sager P, Sarapa N & Wallis R (2014). Cardiac Safety Research Consortium: Can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward. Am Heart J 168, 262-272.
14. Darpo B, Garnett C, Keirns J & Stockbridge N (2015). Implications of the IQ-CSRC prospective study: time to revise ICH E14. Drug Saf 38, 773-780.
15. Dessertenne F (1966). La tachycardie ventriculaire à deux foyers opposés variables. [Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur 59, 263-272.
16. Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, Chivoret G, Schwartz K, Coumel P & Guicheney P (1997). KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 96, 2778-2781.
17. Food and Drug Administration, HHS (2005a). International Conference on Harmonisation: guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice. Fed Regist 70, 61133-61134.
18. Food and Drug Administration, HHS (2005b). International Conference on Harmonisation: guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist 70, 61134-61135.
19. Frothingham R (2001). Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 21, 1468-1472.
20. Haverkamp W, Kruesmann F, Fritsch A, van Veenhuyzen D & Arvis P (2012). Update on the cardiac safety of moxifloxacin. Curr Drug Saf 7, 149-163.
21. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC & Cantilena LR (1993). Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269, 1513-1518.
22. Itoh H, Sakaguchi T, Ding WG, Watanabe E, Watanabe I, Nishio Y, Makiyama T, Ohno S, Akao M, Higashi Y, Zenda N, Kubota T, Mori C, Okajima K, Haruna T, Miyamoto A, Kawamura M, Ishida K, Nagaoka I, Oka Y, Nakazawa Y, Yao T, Jo H, Sugimoto Y, Ashihara T, Hayashi H, Ito M, Imoto K, Matsuura H & Horie M (2009). Latent genetic backgrounds and molecular pathogenesis in drug-induced long QT syndrome. Circ Arrhythm Electrophysiol 2, 511-523.
23. Jamshidi Y, Nolte IM, Dalageorgou C, Zheng D, Johnson T, Bastiaenen R, Ruddy S, Talbott D, Norris KP, Snieder H, George AL Jr, Marshall V, Shakir S, Kannankeril PJ, Munroe PB, Camm AJ, Jeffery S, Roden DM & Behr ER (2012). Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J Am Coll Cardiol 60, 841-850.
24. 2+ current. Circ Res 64, 977-990.
25. Johannesen L, Vicente J, Gray RA, Galeotti L, Loring Z, Garnett CE, Florian J, Ugander M, Stockbridge N & Strauss DG (2014). Improving the assessment of heart toxicity for all new drugs through translational regulatory science. Clin Pharmacol Ther 95, 501-508.
26. Kaab S, Crawford DC, Sinner MF, Behr ER, Kannankeril PJ, Wilde AA, Bezzina CR, Schulze-Bahr E, Guicheney P, Bishopric NH, Myerburg RJ, Schott JJ, Pfeufer A, Beckmann BM, Martens E, Zhang T, Stallmeyer B, Zumhagen S, Denjoy I, Bardai A, Van Gelder IC, Jamshidi Y, Dalageorgou C, Marshall V, Jeffery S, Shakir S, Camm AJ, Steinbeck G, Perz S, Lichtner P, Meitinger T, Peters A, Wichmann HE, Ingram C, Bradford Y, Carter S, Norris K, Ritchie MD, George AL Jr. & Roden DM (2012). A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet 5, 91-99.
27. Kaab S, Hinterseer M, Nabauer M & Steinbeck G (2003). Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome-a case-control pilot study using i.v. sotalol. Eur Heart J 24, 649-657.
28. Kao WH, Arking DE, Post W, Rea TD, Sotoodehnia N, Prineas RJ, Bishe B, Doan BQ, Boerwinkle E, Psaty BM, Tomaselli GF, Coresh J, Siscovick DS, Marban E, Spooner PM, Burke GL & Chakravarti A (2009). Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community-based populations. Circulation 119, 940-951.
29. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, Reynolds W & Rampe D (2005). Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312, 316-323.
30. Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y, Diecke S, Sallam K, Knowles JW, Wang PJ, Nguyen PK, Bers DM, Robbins RC & Wu JC (2013). Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127, 1677-1691.
31. Lu Z, Jiang YP, Wu CY, Ballou LM, Liu S, Carpenter ES, Rosen MR, Cohen IS & Lin RZ (2013). Increased persistent sodium current due to decreased PI3K signaling contributes to QT prolongation in the diabetic heart. Diabetes 62, 4257-4265.
32. Lu Z, Wu CY, Jiang YP, Ballou LM, Clausen C, Cohen IS & Lin RZ (2012). Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl Med 4, 131ra150.
33. Marx SO, Kurokawa J, Reiken S, Motoike H, D'Armiento J, Marks AR & Kass RS (2002). Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science 295, 496-499.
34. Mitcheson JS, Chen J, Lin M, Culberson C & Sanguinetti MC (2000). A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97, 12329-12333.
35. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J & Cantilena LR Jr. (1990). Torsades de pointes occurring in association with terfenadine use. JAMA 264, 2788-2790.
36. Napolitano C, Priori SG, Schwartz PJ, Cantu F, Paganini V, Matteo PS, de Fusco M, Pinnavaia A, Aquaro G & Casari G (1997). Identification of a long QT syndrome molecular defect in drug-induced torsades de pointes. Circulation 96, I-211.
37. Opthof T, Coronel R, Wilms-Schopman FJ, Plotnikov AN, Shlapakova IN, Danilo P Jr, Rosen MR & Janse MJ (2007). Dispersion of repolarization in canine ventricle and the electrocardiographic T wave: T(p-e) interval does not reflect transmural dispersion. Heart Rhythm 4, 341-348.
38. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, Schulze-Bahr E, Haverkamp W, Breithardt G, Cohen N & Aerssens J (2004). Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 82, 182-188.
39. Pezhouman A, Singh N, Song Z, Nivala M, Eskandari A, Cao H, Bapat A, Ko CY, Nguyen TP, Qu Z, Karagueuzian HS & Weiss JN (2015). Molecular basis of hypokalemia-induced ventricular fibrillation. Circulation 132, 1528-1537.
40. Pratt CM, Ruberg S, Morganroth J, McNutt B, Woodward J, Harris S, Ruskin J & Moye L (1996). Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 131, 472-480.
41. Priori SG, Napolitano C & Schwartz PJ (1999). Low penetrance in the long-QT syndrome: clinical impact. Circulation 99, 529-533.
42. Roden DM (1998). Taking the idio out of idiosyncratic - predicting torsades de pointes. Pacing Clin Electrophysiol 21, 1029-1034.
43. Roden DM (2004). Drug-induced prolongation of the QT interval. N Engl J Med 350, 1013-1022.
44. Roden DM (2006). Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med 259, 59-69.
45. Roden DM & Hoffman BF (1985). Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res 56, 857-867.
46. Roden DM & Viswanathan PC (2005). Genetics of acquired long QT syndrome. J Clin Invest 115, 2025-2032.
47. + current: Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96, 195-215.
48. Sarkar AX & Sobie EA (2011). Quantification of repolarization reserve to understand interpatient variability in the response to proarrhythmic drugs: A computational analysis. Heart Rhythm 8, 1749-1755.
49. Schwartz PJ, Ackerman MJ, George AL Jr. & Wilde AAM (2013). Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol 62, 169-180.
50. Selzer A & Wray HW (1964). Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrhythmias. Circulation 30, 17-26.
51. Tomas M, Napolitano C, De Giuli L, Bloise R, Subirana I, Malovini A, Bellazzi R, Arking DE, Marban E, Chakravarti A, Spooner PM & Priori SG (2010). Polymorphisms in the NOS1AP gene modulate QT interval duration and risk of arrhythmias in the long QT syndrome. J Am Coll Cardiol 55, 2745-2752.
52. Vicente J, Johannesen L, Mason JW, Crumb WJ, Pueyo E, Stockbridge N & Strauss DG (2015). Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil. J Am Heart Assoc 4, e001615.
53. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Towbin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD & Keating MT (1996). Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 12, 17-23.
54. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA & Keating MT (1995). SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80, 805-811.
55. Weeke P, Mosley JD, Hanna D, Delaney JT, Shaffer C, Wells QS, Van Driest S, Karnes JH, Ingram C, Guo Y, Shyr Y, Norris K, Kannankeril PJ, Ramirez AH, Smith JD, Mardis ER, Nickerson D, George AL Jr. & Roden DM (2014). Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. J Am Coll Cardiol 63, 1430-1437.
56. Woosley RL, Chen Y, Freiman JP & Gillis RA (1993). Mechanism of the cardiotoxic actions of terfenadine. JAMA 269, 1532-1536.
57. Wu Y, Roden DM & Anderson ME (1999). Calmodulin kinase inhibition prevents development of the arrhythmogenic transient inward current. Circ Res 84, 906-912.
58. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton MS, Murray KT, Norris K, George AL Jr. & Roden DM (2002). Allelic variants in Long QT disease genes in patients with drug-associated torsades de pointes. Circulation 105, 1943-1948.
59. Yang T, Chun YW, Stroud DM, Mosley JD, Knollmann BC, Hong C & Roden DM (2014). Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation 130, 224-234.
60. Yang T, Hong CC & Roden DM (2015). Inhibition of the α-subunit of PI3 kinase increases late sodium current (INa-L) and generates arrhythmias. Heart Rhythm 12, S150.
61. Kr: Implications for torsades de pointes and reverse use-dependence. Circulation 93, 407-411.
62. + current in cardiac cells. Circ Res 80, 782-789.